🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ipatinga
Clinical trial register · Brazil

Clinical Trials in Ipatinga, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Brazil and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2230 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:47 UTC
2230
Studies in scope
all four open statuses
1131
Recruiting now
open to new participants
350
Lead sponsors
across recruiting studies
Top sites
São Paulo 1191 Porto Alegre 890 Rio de Janeiro 476 Curitiba 423 Salvador 342
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Ipatinga

13 of 2230 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Brazil
Start
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
BioNTech SE
Phase 3
480
Ipatinga, Passo Fundo, Porto Alegre, São José do Rio Preto, São Paulo
2025-06-10
Active, closed
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Amgen
Phase 3
315
Fortaleza, Brasília, Cachoeiro de Itapemirim, Vitória, Salvador, Belo Horizonte, Ipatinga, Curitiba
2024-09-09
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
675
Barretos, Curitiba, Florianópolis, Ipatinga, Natal, Porto Alegre, Rio de Janeiro, Santa Maria
2024-04-11
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 3
1,145
Barretos, Florianópolis, Fortaleza, Ijuí, Ipatinga, Londrina, Natal, Porto Alegre
2023-12-14
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC
Phase 3
418
Barretos, Belo Horizonte, Curitiba, Florianópolis, Ipatinga, Pelotas, Porto Alegre, Rio de Janeiro
2022-08-05
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Barretos, Belo Horizonte, Fortaleza, Ipatinga, Jaú, Londrina, Porto Alegre, Rio de Janeiro
2021-12-10
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
776
Belo Horizonte, Curitiba, Florianópolis, Ipatinga, Pelotas, Porto Alegre, Rio de Janeiro, Salvador
2021-11-17
Active, closed
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
BioNTech SE
Phase 2/3
358
Barretos, Belo Horizonte, Caxias do Sul, Curitiba, Ijuí, Ipatinga, Porto Alegre, Rio de Janeiro
2021-01-07
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
696
Barretos, Belo Horizonte, Curitiba, Florianópolis, Fortaleza, Goiânia, Ipatinga, Joinville
2020-09-23
Active, closed
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 3
839
Ipatinga, Natal, Porto Alegre, Barretos, São José do Rio Preto, São Paulo, Rio de Janeiro
2019-08-05
Active, closed
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
NCT03969004Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3
415
Ipatinga, Barretos, Santo Cristo, Passo Fundo, Porto Alegre, Itajaí, Lages, Mogi das Cruzes
2019-06-04
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641Castration-Resistant Prostatic Cancer
Janssen Research & Development, LLC
Phase 3
765
Barretos, Belo Horizonte, Brasília, Curitiba, Fortaleza, Goiânia, Ijuí, Ipatinga
2019-01-25
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
Merck Sharp & Dohme LLC
Phase 3
714
Fortaleza, Salvador, Ipatinga, Natal, Porto Alegre, São José do Rio Preto, Rio de Janeiro, São Paulo
2018-12-17
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Brazilian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-brazil/city/ipatinga

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Brazil and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,230 studies in total at the last sync on 26 Sep 2026, 19:47 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Ipatinga.

How many clinical trials are recruiting in Ipatinga?

4 of the 13 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:47 UTC sync. A further 0 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ipatinga), 13 studies
PhaseStudiesRecruitingShare
Phase 312492.3%
Phase 2/3107.7%

Most active sponsors

Lead sponsors with the most studies (Ipatinga)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC40
AstraZeneca22
BioNTech SE21
Amgen10
Bristol-Myers Squibb10
Johnson & Johnson Enterprise Innovation Inc.11
Merck Sharp & Dohme LLC10
Regeneron Pharmaceuticals10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.